# SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

> **NCT03755115** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Epirubicin plus SHR1210

## Key facts

- **NCT ID:** NCT03755115
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-01
- **Primary completion:** 2019-10-28
- **Final completion:** 2020-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755115, "SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03755115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*